0001179110-21-008140.txt : 20210812
0001179110-21-008140.hdr.sgml : 20210812
20210812100022
ACCESSION NUMBER: 0001179110-21-008140
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210810
FILED AS OF DATE: 20210812
DATE AS OF CHANGE: 20210812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martin Samuel Bates
CENTRAL INDEX KEY: 0001709024
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 211165768
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2021-08-10
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001709024
Martin Samuel Bates
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD
HAMPTON
NJ
08827
0
1
0
0
SVP and CFO
Common Stock
2021-08-10
4
M
0
10302
9.0165
A
21037
D
Common Stock
2021-08-10
4
S
0
2056
45.25
D
18981
D
Common Stock
2021-08-10
4
M
0
11079
2.78
A
30060
D
Common Stock
2021-08-10
4
S
0
682
45.25
D
29378
D
Incentive Stock Option
9.0165
2021-08-10
4
M
0
10302
0.00
D
2028-06-13
Common Stock
10302
16030
D
Incentive Stock Option
2.78
2021-08-10
4
M
0
11079
0.00
D
2029-06-19
Common Stock
11079
31921
D
On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.
25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Anthony S. Marucci, attorney in fact for Samuel Bates Martin
2021-08-12